louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06301152: Lateral Epicondylitis Treatment High Intensive Laser Therapy and Extracorporeal Shock Wave Therapy
Official title: Comparison of High Intensive Laser Therapy and Extracorporeal Shock Wave Therapy in Treatment of Lateral Epicondylitis: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lateral Epicondylitis
Keywords: Lateral Epicondylitis
High Intensive Laser Therapy
Extracorporeal Shock Wave Therapy
Musculoskeletal ultrasound
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two different treatment modalities were applied in two groups
Primary purpose: TREATMENT

Brief summary: Objectives: This study aims to evaluate and compare the short-term efficacy of high-intensity laser therapy (HILT) and extra corporeal shock wave therapy(ESWT) on pain, sensitivity, handgrip strength, and functions in the treatment of lateral epicondylitis (LE).

Material and methods: Forty five participants (age range, 18 to 65 years) with unilateral elbow pain were randomized into two groups. HILT group (n = 22) and the ESWT group (n = 23). The HILT and ESWT were administered three times a week for three weeks, and each treatment was combined with exercises. All patients in both groups were evaluated with ultrasonography for common extensor tendon(CET) thickness. A visual analog scale (VAS), Quick Disabilities of the Arm, Shoulder, and Hand (QDASH), and hand grip strength test were used to evaluate the patients before, one, and six weeks after treatment.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Lateral epicondylitis
* Age \>18

Exclusion Criteria:

* Operation history about elbow
* Received physical therapy, or had a steroid injection to the elbow in the three months
* Cervical radiculopathy,
* Elbow deformities,
* Fibromyalgia syndrome,
* Carpal tunnel syndrome,
* Neurological impairments in the upper extremity,
* Chronic inflammatory conditions,
* Hemophilia,
* Pregnant,
* History of malignancy

Primary outcomes:
measure: Visual analog scale
timeFrame: Baseline, 1 week and 6 weeks
Secondary outcomes:
measure: Quick Disability Arm, Shoulder and Hand questionary,
timeFrame: Baseline, 1 week and 6 weeks
measure: hand grip strength
timeFrame: Baseline, 1 week and 6 weeks
measure: musculoskeletal ultrasonography
timeFrame: Baseline, 1 week and 6 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Emine Esra Bilir
state: Çankaya
Study officials:
References:
Clinical trial NCT01097252: Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer
Official title: Randomized Trial of Concurrent Chemoradiation With Weekly Versus Three-week Cisplatin in Patients With Advanced Cervical Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cervical Cancers
Keywords: Cervical Neoplasm
chemoradiation
compliance
toxicity
Lead sponsor: Korea Cancer Center Hospital
Sponsor class: OTHER
First posted: 2010-04-01
Enrollment: 104
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Three weekly cisplatin based chemoradiation is to be compared the compliance, toxicity, and response rates with the weekly cisplatin based chemoradiation in the treatment of locoregionally advanced cervical cancers.

Detailed description: This study is to compare the compliance, toxicity, response and survival rate between concurrent chemoradiation with weekly cisplatin 40mg/m2 and three-week cisplatin 75mg/m2 in patients with advanced cervical cancer. Patients with primary untreated invasive squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix from stage IIB to IVA were enrolled. Patients with histologically proven locoregionally advanced cervical cancer will be randomized into two treatment arm; Arm I, concurrent chemoradiation with weekly cisplatin 40mg/m2 for six times; Arm II, concurrent chemoradiation with three-week cisplatin 75mg/m2 for three times. The compliance and toxicity during the chemoradiation is the primary endpoint. Response rate and the overall survival will be analyzed as secondary endpoints.

Eligibility criteria: Inclusion Criteria:

* Histologically proven cervical cancer
* Squamous, Adenosquamous, Adeno carcinoma cell type
* International Federation of Gynecologic Oncology (FIGO) stage IIB - IVA
* Gynecologic Oncology Group (GOG) performance status 0 - 2

Exclusion Criteria:

* Previous history of chemotherapy or radiation
* History of other cancer
* Hypersensitivity to platinum agents
* Pregnancy
* Serious medical disease

Primary outcomes:
measure: compliance
timeFrame: 3 month
Secondary outcomes:
measure: survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea Institute of Radiological & Medical Sciences
Study officials:
affiliation: Korea Institute of Radiological & Medical Sciences
name: Sang-Young Ryu, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81. doi: 10.1016/j.ijrobp.2011.05.002. Epub 2011 Aug 11.
Clinical trial NCT01939652: Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair
Official title: Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Abdominal Aortic Aneurysm > 5.5 cm Effect of a Restricted Intravenous Fluid Regime on Complications and Hospital Stay After the Minilaparotomy AAA Repair.
Keywords: minilaparotomy
AAA
fluid regime
Lead sponsor: University Clinical Center Tuzla
Sponsor class: OTHER
First posted: 2013-09-11
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Elective minilaparatomy abdominal aortic aneurysm (AAA) repair is associated with a significant number of complications involving respiratory, cardiovascular, gastrointestinal and central nervous system, and mortality ranging up to 5%. In our study, we tested the hypothesis that intraoperative and postoperative intravenous restrictive fluid regime reduces postoperative morbidity and mortality and improves the outcome of the treatment of minilaparotomy AAA repair.

Detailed description: We investigate effects of a restricted fluid regime versus standard regimen on complications and hospital stay after minilaparatomy aortic aneurysm repair.

Eligibility criteria: Inclusion Criteria:

* AAA more than 5,5 cm in diameter tube graft

Exclusion Criteria:

* emargency comorbidity maligancy

Primary outcomes:
measure: Number of major and minor complications
timeFrame: 30 days
Secondary outcomes:
measure: ICU and duration of Hospital stay
timeFrame: 30 days
measure: In-hospital mortality, 30-days mortality
timeFrame: 30 days
measure: Fluid balance (daily and cumulative)
timeFrame: 3 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05285852: Effects Of Dry Needling On Sternocleidomastoid Muscle For Pain And Disability In Migraine
Official title: The Effects of Triggering Points Dry Needling on Sternocleidomastoid Muscle for Pain and Disability in Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine
Keywords: Dry Needling
Sternocleidomastoid Muscle
Pain
Disability
Randomized Control Trial
Migraine
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-03-18
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the effects, sequel of dry needling in migraine by resolving MTrPs in sternocleidomastoid muscle.

To determine the possession of dry needling technique to mitigate the frequency, intensity and duration of headache.

To determine the effectiveness of dry needling in the disability hindrance in migraine patients.

Detailed description: This is a randomized control study of 60 volunteers with migraine induced by myofacial triggers in sternocleidomastoid muscle. The migraine will be diagnosed by the neurologist and for the evaluation of trigger points and muscle thickness ultrasound will be done. After the diagnostic procedure and complete history evaluation from the selected population 30 subjects will be subjected to dry needling group and 30 others will be kept in the placebo group. All the participants will receive six sessions at the myofascial trigger point area there should be the gap of at least 48 hours between two sessions. As for the assessment details, such as the frequency, intensity and duration of the headaches; the consumption of drugs; the thickness of SCM muscles; the pain pressure threshold and the cervical range motions will be recorded before, immediately following the response, and at the 1-month follow-up

Eligibility criteria: Inclusion Criteria:

* Submitted with a headache diagnosis by a neurologist.
* Presence of active Trigger points in the Sternocleidomastoid muscle reproducing the symptoms of migraine.
* Active trigger points will be identified if "there is muscle sensitivity that has been activated by pressure and reproduces the patient's referred pain and headache."
* A jump sign the characteristic behavioral response to compression on a trigger point, will be produced.

Exclusion Criteria:

* background of neck trauma
* cervical radiculopathy
* History of head/shoulder surgery
* Diagnosis of other unusual headaches/migraines
* Phobia of pricking
* pregnancy

Primary outcomes:
measure: Visual Analogue Scale
timeFrame: 12th Week
measure: Bubble Inclinometer
timeFrame: 12th Week
measure: Sternocleidomastoid muscle Ultrasonography
timeFrame: 12th Week
Secondary outcomes:
Other outcomes:
Locations:
city: Faisalabad
country: Pakistan
facility: Ripah International University
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Kashif
role: STUDY_CHAIR
References:
Clinical trial NCT04004052: Conservative Treatment and Ultrasound Guided Injection for Treatment Meralgia Paresthetica
Official title: Conservative Treatment Versus Ultrasound Guided Injection in Management of Meralgia Paresthetica: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Meralgia Paresthetica
Keywords: Meralgia paresthetica
Ultrasound-guided injection
Transcutaneous electrical nerve stimulation
Lead sponsor: Fatih Sultan Mehmet Training and Research Hospital
Sponsor class: OTHER
First posted: 2019-07-01
Enrollment: 54
Sex: ALL
Minimum age (years): 42
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Meralgia paresthetica (MP) is an entrapment mononeuropathy of the lateral femoral cutaneous nerve (LFCN), where conservative treatment options are not always sufficient.

The aim of this study was to evaluate the efficacy of ultrasound (US) guided lateral femoral cutaneous nerve injection in the management of meralgia paresthetica by comparing with transcutaneous electrical nerve stimulation (TENS) therapy and sham transcutaneous electrical nerve stimulation therapy.

Detailed description: In this prospective, randomized, sham-controlled study, fifty four patients (23 female and 31 male, the mean age 53.61±11.99 years) with lateral femoral cutaneous nerve compression with clinical and electrophysiological findings were enrolled. Patients were randomly assigned to three groups: 1) Ultrasound-guided injection group, 2) TENS group, 3) Sham TENS group. The blockage of the lateral femoral cutaneous nerve was performed for therapeutic meralgia paresthetica management in group 1. Ten sessions of conventional TENS were administered to each patient 5 days a week for 2 weeks, for 20 minutes per daily session in Group 2, and sham TENS was applied to group 3 with the same protocol.

Visual Analog Scale (VAS), painDETECT questionnaire (PD-Q), Semmes Weinstein monofilament test (SWMt), Pittsburgh Sleep Quality Index (PSQI) and health-related quality of life (SF 36), at onset (T1), 15 days after treatment (T2) and 1 month after treatment (T3) were used for evaluation.

Eligibility criteria: Inclusion criteria

* Patients diagnosed with LFCN entrapment confirmed by clinical and electrophysiological findings

Exclusion criteria

* Secondary entrapment neuropathy
* Malignancy
* Pregnancy
* Infection in the inguinal region or dermatitis
* Lumbar radiculopathy
* Cardiac pacemakers
* Polyneuropathy

Primary outcomes:
measure: Visual Analog Scale
timeFrame: 1 months
measure: painDETECT questionnaire
timeFrame: 1 months
measure: Semmes-Weinstein monofilament test
timeFrame: 1 months
Secondary outcomes:
measure: Short Form (SF-36) Health Questionnaire
timeFrame: 1 months
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 1 Months
Other outcomes:
Locations:
Study officials:
affiliation: Fatih Sultan Training and Research Hospital
name: Gülcan Öztürk, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07012252: Optical Coherence Tomography of the Irido-Corneal Angle Before and After Goniotomy and Trabeculotomy in Primary Congenital Glaucoma
Official title: Optical Coherence Tomography of the Irido-Corneal Angle Before and After Goniotomy and Trabeculotomy in Primary Congenital Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Optical Coherence Tomography
Anterior Chamber Angle
Goniotomy
Trabeculotomy
Primary Congenital Glaucoma
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 32
Sex: ALL
Minimum age (years): 1
Maximum age (years): 72
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The research aimed to improve surgical techniques and long-term outcomes by utilizing this advanced imaging technology to illuminate the structural abnormalities of the anterior segment in eyes with primary congenital glaucoma.

Detailed description: Primary congenital glaucoma (PCG) is a rare disease, but it is responsible for 2.5%-15% of all documented cases of pediatric blindness.

The main target of the treatment of pediatric glaucoma is to control the IOP surgically. However, medical treatment could be instituted as a temporary and/or adjunctive option to maximize Intraocular pressure (IOP) control. Initial goniotomy or trabeculotomy have been detected to have high success rates. Trabeculotomy has a comparable long-term success rate in most patients of PCG. The success rate of trabeculotomy is lower in advanced or late-presenting patients.

Eligibility criteria: Inclusion Criteria:

* Age from 1 to 72 weeks.
* Both sexes.
* Infants with primary congenital glaucoma.

Exclusion Criteria:

* Eyes in which the angle could not be visualized by the handheld anterior segment optical coherence tomography (HH AS-OCT).
* Eyes with previous intraocular surgery.

Primary outcomes:
measure: Central corneal thickness
timeFrame: 6 months post-procedure
Secondary outcomes:
measure: Trabecular-iris angle
timeFrame: 6 months post-procedure
measure: Iris thickness
timeFrame: 6 months post-procedure
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT02241252: Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients
Official title: Clinical Validation of an iPhone ECG System, QT Substudy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Arrhythmia
Qt Interval, Variation in
Keywords: ECG
QT interval
Sotalol
Dofetilide
iPhone
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
First posted: 2014-09-16
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This study will validate the recording accuracy of a specific electrical interval of the heart, the QT interval, between an iPhone rhythm strip recording and a traditional 12-lead electrocardiogram (ECG). These measurements will occur in hospitalized patients that are starting either sotalol or dofetilide, since both of these medications can prolong the QT interval.

Detailed description: Patients that were already selected to begin either dofetilide or sotalol in the hospital, will be included in the study. Patients will receive an ECG before and 2 hours after each dose of the medication, which is done to monitor the QT interval. In addition, patients that consent to participate in the study will have an iPhone ECG recording taken in lead positions that correspond to leads I,II, and III.

These recordings will be compared and analyzed to assess the accuracy of the QT interval recordings between the two methods.

Eligibility criteria: Inclusion Criteria:

* initiation of sotalol or dofetilide
* inpatient at University hospital

Exclusion Criteria:

* none

Primary outcomes:
measure: QT interval measurement (in milliseconds)
timeFrame: Participants will be followed for duration of hospital stay during which dofetilide or sotalol are being started, an expected average of 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: University of Oklahoma
name: Paul J Garabelli, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Oklahoma
name: Dwight W Reynolds, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00776932: Chronic Knee Pain Study
Official title: Disparity in Joint Replacement: Pathway to Intervention
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Knee Osteoarthritis
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2008-10-22
Enrollment: 852
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: African Americans and Whites over the age of 50 with chronic knee pain.

Brief summary: Specific Aims: 1) To examine differences between AA and white patients with knee OA in willingness to consider knee joint replacement. 2) To examine the relationship between socio-cultural factors and patient willingness to consider joint replacement. 3) To examine how demographic, socio-cultural, and clinical factors mediate the relationship between race and patient willingness. 4) To examine the relationship between patient willingness and referral to orthopedic care for knee OA (secondary aim).

Experimental design/Methodology: A cross-sectional survey study design will be used to examine socio-cultural and clinical factors that may vary by race/ethnicity and may be determinants of willingness to consider joint replacement as a treatment option. Patients with symptomatic and radiographic knee OA from the primary care clinics will be surveyed. Only individuals with knee OA of sufficient severity that would be considered candidates for joint replacement will be included. Analytic strategies include ordinal logistic regression, path analysis, and regression trees.

Subject population: The study sample will consist of approximately 133 African American and 419 white patients with OA of the knee in a primary care setting.


Eligibility criteria: Inclusion Criteria:

* over age 50
* chronic knee pain
* radiographic evidence of knee OA

Exclusion Criteria:

* previous joint replacement
* inflammatory arthritis

Primary outcomes:
measure: Compared to whites, AAs with knee OA will be less willing to consider joint replacement. Logistic regression will be used to model the categorical measure of willingness, if preliminary analyses indicate dichotomizing this measure.
timeFrame: Study Completion
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburh Arthritis Research Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: C. Kent Kwoh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01785732: Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Resistant Hypertension
Lead sponsor: The Hospital District of Satakunta
Sponsor class: OTHER
First posted: 2013-02-07
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypertension is a major risk factor for stroke and cardiovascular mortality. Catheter- based renal denervation causes substantial and sustained blood- pressure reduction in patients with resistant hypertension.

The purpose of RENSYMPIS is to study the effects of renal denervation on:

1. Cardiovascular function
2. Metabolic factors
3. Inflammatory and endocrine factors
4. Coagulation
5. Sleep


Eligibility criteria: Inclusion Criteria:

* Resistant Hypertension (systolic blood pressure \>160mmHg and 3 or more antihypertensive agents in use)
* Age 30- 69 years
* Written informed consent

Exclusion Criteria:

* Secondary hypertension
* Pseudohypertension
* Pregnancy
* Renal insufficiency (GFR \<45ml/min)
* Clinically significant stenotic valvular disease
* Oral anticoagulation
* CCS III-IV symptoms or CABG/PCI in previous 6 months
* Prior stroke
* Contrast agent allergy
* inappropriate renal artery anatomy (\< 4mm diameter, \< 20mm length)

Primary outcomes:
measure: Office blood pressure
timeFrame: 2 years
Secondary outcomes:
measure: Ambulatory blood pressure
timeFrame: 2 years
measure: Insulin resistance
timeFrame: 2 years
measure: Endothelial function
timeFrame: 2 years
Other outcomes:
Locations:
city: Pori
country: Finland
facility: Satakunta Central Hospital
Study officials:
References: